Search Results
Aug 20, 2026, 20:00 ET Sunshine Guojian Releases 2026 Interim Report:
application for OX40L/IL-31RA bispecific antibody injection (R&D code: 716) for atopic dermatitis has been approved by the NMPA and U.S. Food and Drug Administration (FDA). Enrollment of healthy Chinese subjects in a Phase I clinical study has been initiated.Accelerated Translation of Cutting-Edge
More news about: 3SBio Inc.
Aug 20, 2026, 18:23 ET Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration's (FDA) recent clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome,
More news about: Atrium Therapeutics
Aug 20, 2026, 17:01 ET FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer's, Building on Groundwork Laid by Early ADDF Investment
match the right drugs to the right patient at the right time."About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the development of drugs to prevent,
More news about: Alzheimer's Drug Discovery Foundation
Aug 20, 2026, 16:30 ET Perimeter Announces Preliminary Second Quarter 2026 Financial Results
ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Claire™, recently approved by the U.S. Food and Drug Administration (FDA), is our next-generation AI-enabled device. The Company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast
More news about: Perimeter Medical Imaging AI Inc.
Aug 20, 2026, 16:15 ET Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
Abbott stands by the safety of these products and the essential role they play in helping the medical community care for preterm infants. The Food and Drug Administration, National Institutes of Health, Centers for Disease Control and Prevention, American Academy of Pediatrics, NEC Society, neonatologists
More news about: Abbott
Aug 20, 2026, 14:20 ET The Lustgarten Foundation Announces New Pancreatic Cancer Research Funding Totaling $22.8 Million In Fiscal Year 2026
personalized treatment approach for an aggressive subtype of pancreatic cancer by using a novel test to identify eligible patients and comparing a targeted drug combination with standard chemotherapy.Harshabad Singh, MBBS, MD, Mass General Brigham Cancer Institute, for his study "A phase 2
More news about: Lustgarten Foundation
Aug 20, 2026, 13:49 ET Vascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease
hypoxic vascular environment could yield a circulating RBC population with less cumulative sickling-related oxidative injury, independent of any direct drug effect on hemoglobin.Catalytic membrane and antioxidant stabilization: Curcuminoids delivered transdermally or sublingually
More news about: Vascarta Inc.
Aug 20, 2026, 13:33 ET Bucked Up® Launches Hunt: Orange Cream, a Limited-Edition Flavor Built to Fuel Your Hunt
and Walmart, united by one belief: everyone deserves to Feel Like a Million Bucks™.These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
More news about: Bucked Up
Aug 20, 2026, 13:12 ET The Sugar Association: Sweetener transparency more relevant and needed than ever
WASHINGTON, Aug. 20, 2026 /PRNewswire/ -- The Sugar Association today (Thursday) renewed its call for the U.S. Food and Drug Administration (FDA) to end decades of inaction and require transparent labeling of non-sugar sweeteners ("sweeteners"), in line with the Make America
More news about: The Sugar Association
Aug 20, 2026, 13:03 ET AARD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aardvark Therapeutics Securities Lawsuit - Contact SueWallSt
indicated that sell-side models were built on the Company's representation that ARD-101 was an oral, "gut-restricted" therapy with roughly 99% of the drug remaining in the digestive tract. The complaint contends those safety representations were materially misleading and that ARD-101's clinical, regulatory,
More news about: SueWallSt.com
Aug 20, 2026, 13:03 ET SueWallSt Reminds Wise Group plc Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 29, 2026 - WSE
euros (approximately $582.5 million) in suspicious transactions, with alleged links to fraud, corruption and drug trafficking. The prosecutor's office indicated the inquiry began the prior year, was nearing completion, and that prosecutors were finalizing a direct
More news about: SueWallSt.com
Aug 20, 2026, 11:30 ET U.S. Recall Volume Exceeds One Billion Units in 2026
inflators.Test results released in April showed that the U.S. infant formula supply is largely free of chemical contaminants, and the U.S. Food and Drug Administration committed to continued testing. The agency also finalized its new post-market assessment program for food chemical safety."Recall
More news about: Sedgwick Claims Management Services, Inc.
Aug 20, 2026, 10:31 ET Radiotherapy-Induced Oral Mucositis Market Set for Strong Growth Through 2036, Driven by Emerging Therapies and Rising Cancer Burden | DelveInsight
11.2.1Drug Description11.2.2
More news about: DelveInsight Business Research, LLP
Aug 20, 2026, 10:30 ET Biobanking Market worth $12.38 billion by 2031 - Exclusive Report by MarketsandMarkets™
collection, preservation, and long-term storage to maintain sample quality and integrity. Growing demand for high-quality biological samples for genomics, drug discovery, precision medicine, clinical research, and cell and gene therapy is increasing the need for reliable collection and storage infrastructure.
More news about: MarketsandMarkets
Aug 20, 2026, 10:09 ET Keymed Biosciences Announces 2026 H1 Results and Business Updates
support key drug development functionalities, including antibody screening, small molecule lead compound discovery, antibody conjugation, functional evaluation, in vivo preclinical studies and biomarker identification. We have the expertise and capability to independently complete the entire drug development
More news about: Keymed Biosciences
Aug 20, 2026, 10:00 ET Springbuk by Truven: Employee Health Trends Report Finds 7.1% Rise in Employer Healthcare Costs for 2025
Prescription drug costs outpaced medical spend, with Rx PMPM rising 10.9% to $157.60 and now representing roughly one-quarter of total healthcare spend. Medical PMPM
More news about: Truven by Merative
Aug 20, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR
information about joining the class action]In late 2024, Capricor submitted its Biologics License Application ("BLA") to the U.S. Food and Drug Administration for Deramiocel as a cell therapy for the treatment of Duchenne muscular dystrophy. In July 2025, the FDA issued a Complete Response
More news about: Pomerantz LLP
Aug 20, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
2, 2026.Then, on May 14, 2026, Aardvark issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company's previously announced voluntary pause." The press release
More news about: Pomerantz LLP
Aug 20, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Wise Group plc of Class Action Lawsuit and Upcoming Deadlines - WSE
nearing completion, concerns potential money laundering offences, with alleged links to fraud, corruption and drug trafficking" and that "[p]rosecutors are investigating whether Wise Europe's services were used by international criminal organisations,
More news about: Pomerantz LLP
Aug 20, 2026, 10:00 ET UPSHER-SMITH EXPANDS PORTFOLIO WITH LAUNCH OF GLATIRAMER ACETATE INJECTION
The Therapeutic Equivalence (TE) code for Upsher-Smith's Glatiramer Acetate Injection product is AP, and the Reference Listed Drug (RLD) is the brand COPAXONE® (glatiramer acetate injection)**."The launch of Glatiramer Acetate Injection marks another important
More news about: Upsher-Smith Laboratories, LLC
Aug 20, 2026, 10:00 ET Perelel's Latest Clinical Study Proves Efficacy Of Triple-Support Protein To Show Significant Benefits Across Metabolic and Cognitive Health in Women
perelelhealth.com.*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.About Perelel
More news about: Perelel
Aug 20, 2026, 09:54 ET AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Class Action
stock price plummeted over 56%. May 14, 2026: Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and
More news about: Hagens Berman Sobol Shapiro LLP
Aug 20, 2026, 09:37 ET Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the U.S. Food and Drug Administration (FDA) prior to resubmitting its Biologics License Application (BLA).The HOPE-3 Trial Breakthrough and Subsequent Capital
More news about: Hagens Berman Sobol Shapiro LLP
Aug 20, 2026, 09:37 ET Lupin und Tenpoint Therapeutics geben strategische Partnerschaft zur Vermarktung von YUVEZZI™ in der Europäischen Union, dem Vereinigten Königreich, der Schweiz, Norwegen und Island bekannt
Brimonidintartrat-Augentropfen) 2,75 %/0,1 % ist ein einmal täglich anzuwendendes Zweikomponenten-Augentropfenpräparat, das von der US-amerikanischen Food & Drug Administration (FDA) zur Behandlung von Presbyopie zugelassen ist, einer Erkrankung, die durch den allmählichen Verlust der Nahsehschärfe gekennzeichnet
More news about: Lupin Limited
Aug 20, 2026, 09:09 ET Lupin et Tenpoint Therapeutics annoncent un partenariat stratégique visant à commercialiser YUVEZZI™ dans l'Union européenne, au Royaume-Uni, en Suisse, en Norvège et en Islande
2,75 % de carbachol et 0,1 % de tartrate de brimonidine) est un collyre à double principe actif, à prise unique quotidienne, approuvé par la Food & Drug Administration (FDA) des États-Unis pour le traitement de la presbytie, une affection caractérisée par une perte progressive de l'acuité visuelle de
More news about: Lupin Limited